TMCnet News
AGTC Announces Data to be Presented from the Ongoing XLRP and Achromatopsia Clinical Trials at the ARVO 2021 Virtual Annual MeetingGAINESVILLE, Fla. and CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that data from the ongoing X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM) clinical trials will be presented at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Virtual Annual Meeting. Paul Yang, MD, PhD, will present interim data from the XLRP Phase 1/2 trial and Mark Pennesi, MD, PhD, will present interim data from the ACHM Phase 1/2 clinical trials. Details of XLRP Presentation: Session Title: Six-Month Findings from a Phase 1/2 Clinical Study of Subretinal Gene Therapy Drug AGTC-501 for X-Linked Retinitis Pigmentosa Show Clinically Meaningful Improvement in Macular Sensitivity Lead Presenter: Paul Yang, MD, PhD, Casey Eye Institute, Oregon Health & Science University, Assistant Professor, XLRP Investigator Session Date: Monday, May 3, 4:30-6:00 PM EDT Details of ACHM Presentation: Session Title: 12-Month Findings from Two Phase 1/2 Clinical Studies of Subretinal Gene Therapy Drugs for Achromatopsia Lead Presenter: Mark Pennesi, MD, PhD, Casey Eye Institute, Orego Health & Science University, Assistant Professor, ACHM Investigator Session Date: Thursday, May 6, 5:15-6:45 PM EDT About AGTC IR/PR CONTACTS: Corporate Contacts: Stephen Potter |